Employees: 1,403
Size Stratec (SBS.DE) is a Germany Health Care company (Medical Specialties) with a market value of $365M, the 188th largest of 198 Germany companies the cockpit tracks. Shares closed at €27.35 on 18 Nov 2026.
Performance Over six months the shares gained 62.8%, against -15.0% for the median peer and -0.9% for the Germany market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue fell 6.2% over the last twelve months (peer median +10.5%); the operating margin is 3.5% (peer median 12.2%).
Valuation It trades at 18.2× forward earnings against a peer median of 17.5× (6th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.9 points below its cost of capital (7.0% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €240M | €251M | €258M | €270M | €275M |
| Revenue growth | — | -3% | -5% | -2% | — |
| Gross profit | €62.8M | €64.2M | €76.4M | €68.2M | €79.5M |
| EBITDA | €54.3M | €27.2M | €44.9M | €45.8M | €58.9M |
| Net income | -€42.4M | -€242,000 | €16.0M | €15.4M | €29.2M |
| Free cash flow | €34.6M | -€9.71M | €38.8M | €11.0M | -€18,000 |
| Capital expenditure | €12.2M | €16.2M | €18.2M | €17.3M | €19.0M |
| Total debt | €110M | €132M | €131M | €142M | €87.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SBS.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.6% | -12.0% | highest of 21 |
| 6-month return | +62.8% | -15.0% | 3rd highest of 20 |
| Distance from 52-week high | -4.5% | -44.8% | highest of 21 |
| Revenue growth (TTM) | -6.2% | +10.5% | 5th lowest of 21 |
| Operating margin | 3.5% | 12.2% | 7th lowest of 21 |
| Forward P/E | 18.2× | 17.5× | 6th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 19.1% | -5.3% | 3rd most demanding of 15 |
| Growth delivered (Del g) | +0.1% | +4.8% | 6th lowest of 15 |
| Hurdle (Req g minus delivered) | +19.0 pp | -2.0 pp | 2nd most demanding of 15 |
| ROIC minus cost of capital | -4.9 pp | +8.5 pp | 6th lowest of 19 |
| EV / EBITDA | 7.8× | 10.6× | 5th cheapest of 13 |
| Net debt / EBITDA | 1.6× | -2.8× | 3rd most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 16.4× | 5.7% | +3.4% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 20.3× | 24.9% | +18.8% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 25.3× | -4.2% | -6.0% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 36.0× | 18.4% | +4.4% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | n/a | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | n/a | 17.1% | +18.1% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | n/a | -12.7% | -1.3% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 37.2× | n/a | n/a |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 11.3× | -10.3% | +16.9% |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 3.8× | -19.9% | -0.1% |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | n/a | -9.5% | -6.6% |
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | n/a | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | n/a | n/a | n/a |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | n/a | n/a | n/a |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 15.2× | -6.3% | +247.0% |
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 25.2× | -0.3% | -0.7% |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 8.4× | -17.6% | +15.4% |
| Nanjing Medlander Medical Technology 688273.SS | China | $337M | -47% | -12% | 8% | 17.5× | 35.3% | +5.2% |